[Source: SK Biopharmaceuticals Co.]
South Korea’s SK Biopharmaceuticals Co. has launched its anti-epileptic drug cenobamate in Europe, one year after successfully entering the U.S. market.
Angelini Pharma, SK Biopharm’s European partner based in Italy, announced Wednesday the Korean drug maker’s epilepsy drug has hit the German market under the brand name ONTOZRY®, making it the first case of entry into Europe and the U.S. with a therapeutic compound independently discovered and developed by a Korean pharmaceutical company.
Shares of SK Biopharm finished Wednesday up 3.78 percent at 123,500 won ($110.56) in Seoul.
In the U.S., cenobamate sells under the brand name XCOPRI® for the treatment of partial-onset seizures in adults.
The epilepsy drug received marketing authorization from the European Commission in late March and has been cleared for sale by the U.K. drug regulatory authority early this month.
Starting with Germany, the drug is scheduled to be launched in 41 European countries from the third quarter. SK Biopharm expects that it will be able to receive royalty fees and milestone payments from Angelini Pharma following expansion into the European market.
Epilepsy afflicts approximately 400,000 people in Germany, according to data from global research firm Decision Resources Group.
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]